UNSPSC 85811603: Introduction of other antineoplastic into cranial cavity and brain, via natural or artificial opening

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of other antineoplastic into cranial cavity and brain, via natural or artificial opening. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0Q705

UNSPSC 85811603, a Commodity code for introduction of antineoplastic agents into the cranial cavity and brain via natural or artificial opening, shows minimal relevance to actual state and local government procurement activity. The recent opportunities dataset tagged under this code reflects healthcare service procurement that diverges substantially from the code's clinical-procedure nomenclature.

The four opportunities posted under this code span different service categories: Inland Empire Health Plan (IEHP) in California issued an RFI on October 16, 2026 seeking 24/7/365 virtual urgent care services through board-certified physicians with authority to prescribe medications (response due October 31, 2026); DeKalb County, Georgia issued an RFP on October 12, 2026 for medical services under an annual contract with four one-year renewal options (response due November 12, 2026); the Nevada Health Authority issued two significant RFPs—one on October 8, 2026 for Program of All Inclusive Care for the Elderly (PACE) operations across Nevada (response due December 10, 2026) and another on October 7, 2026 for a Rural Value Acceleration Network vendor to facilitate value-based care transformation (response due November 30, 2026). The PACE solicitation represents the most substantive opportunity, establishing fixed monthly capitation rates by service area (Clark County, Washoe County, and Rural Counties) ranging from $4,532.24 to $8,804.32 per participant, with a contract term through December 31, 2032 and optional four-year extension. The code sees activity from health plans and state health authorities in California, Georgia, and Nevada, but the opportunities themselves target broader healthcare administration, urgent care delivery, and managed long-term care operations rather than neurosurgical or oncological intervention. This mismatch between the code's clinical scope and the practical procurement activity suggests the code assignment reflects administrative classification error rather than meaningful targeting of suppliers in antineoplastic drug delivery.